Your browser doesn't support javascript.
loading
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.
Galot, Rachel; Le Tourneau, Christophe; Saada-Bouzid, Esma; Daste, Amaury; Even, Caroline; Debruyne, Philip; Henry, Stéphanie; Zanetta, Sylvie; Rutten, Anemie; Licitra, Lisa; Canon, Jean-Luc; Kaminsky, Marie-Christine; Specenier, Pol; Rottey, Sylvie; Guigay, Joël; Kong, Anthony; Tinhofer, Inge; Borcoman, Edith; Dirix, Lieve; Raveloarivahy, Tiana; Fortpied, Catherine; Vanlancker, Maureen; Morfouace, Marie; Govaerts, Anne-Sophie; Machiels, Jean-Pascal.
Afiliação
  • Galot R; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200 Brussels, Belgium. Electronic address: rachel.galot@uclouvain.be.
  • Le Tourneau C; Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Versailles-Saint-Quentin-en-Yvelines University, Montigny-le-Bretonneux, France. Electronic address: christophe.letourneau@curie.fr.
  • Saada-Bouzid E; Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France. Electronic address: esma.saada-bouzid@nice.unicancer.fr.
  • Daste A; Département d'Oncologie Médicale, Hôpital Saint André, CHU de Bordeaux, 1 Rue Jean Burguet, 33075, Bordeaux Cedex, France. Electronic address: amaury.daste@chu-bordeaux.fr.
  • Even C; Head and Neck Department, Gustave Roussy, Villejuif, France. Electronic address: caroline.even@gustaveroussy.fr.
  • Debruyne P; Kortrijk Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium; School of Life Sciences, Anglia Ruskin University, Cambridge, UK. Electronic address: PHILIP.DEBRUYNE@azgroeninge.be.
  • Henry S; Université Catholique de Louvain, CHU UCL Namur, Département d'oncologie Médicale, Site Ste Elisabeth, Place Louise Godin 15, B5000, Namur, Belgium. Electronic address: stephanie.henry@uclouvain.be.
  • Zanetta S; Département d'oncologie Médicale, Centre GF Leclerc, 1 Rue Du Pr Marion, 21000 DIJON, France. Electronic address: szanetta@cgfl.fr.
  • Rutten A; GZA Hospitals, Antwerp, Belgium. Electronic address: Annemie.Rutten.Oncologie@gza.be.
  • Licitra L; Head and Neck Cancer Medical Oncology Department, Fondazione IRCCS "Istituto Nazionale Dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Italy. Electronic address: lisa.licitra@istitutotumori.mi.it.
  • Canon JL; Grand Hôpital de Charleroi, Pôle Cancer et Maladies Du Sang, Site Notre Dame, Grand Rue 3, 6000 Charleroi, Belgium. Electronic address: Jean-Luc.Canon@ghdc.be.
  • Kaminsky MC; Institut de Cancérologie de Lorraine - Alexis Vautrin, 6 Avenue de Bourgogne - CS 30519, 54519 Vandoeuvre-les-Nancy Cedex, France. Electronic address: mc.kaminsky@nancy.unicancer.fr.
  • Specenier P; Universitair Ziekenhuis Antwerpen, Wilrijkstraat 10, 2610 Edegem, Belgium. Electronic address: Pol.Specenier@uza.be.
  • Rottey S; Drug Research Unit Ghent and Department Medical Oncology, Universitair Ziekenhuis Gent, C. Heymanslaan 10, 9000 Gent, Belgium. Electronic address: sylvie.rottey@ugent.be.
  • Guigay J; Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2, France. Electronic address: Joel.GUIGAY@nice.unicancer.fr.
  • Kong A; Comprehensive Cancer Centre, King's College London, Guy's Campus, Room 2.36b New Hunt's House, London SE1 1UL, UK. Electronic address: anthony.kong@kcl.ac.uk.
  • Tinhofer I; Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Department of Radiooncology and Radiotherapy, Charitéplatz 1, 10117, Berlin, Germany. Electronic address: ingeborg.tinhofer@charite.de.
  • Borcoman E; Department of Drug Development and Innovation, Institut Curie, Paris, Saint-Cloud, France. Electronic address: edith.borcoman@curie.fr.
  • Dirix L; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: lieve.dirix@eortc.org.
  • Raveloarivahy T; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: tiana.raveloarivahy@eortc.org.
  • Fortpied C; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: catherine.fortpied@eortc.org.
  • Vanlancker M; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: maureen.vanlancker@eortc.org.
  • Morfouace M; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: marie.morfouace@eortc.org.
  • Govaerts AS; European Organization of Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium. Electronic address: anne-sophie.govaerts@eortc.org.
  • Machiels JP; Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Avenue Hippocrate 10, 1200 Brussels, Belgium. Electronic address: jean-pascal.machiels@uclouvain.be.
Eur J Cancer ; 158: 17-26, 2021 Oct 09.
Article em En | MEDLINE | ID: mdl-34638090
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies Idioma: En Revista: Eur J Cancer Ano de publicação: 2021 Tipo de documento: Article